Loading
Payers would promise in advance to buy a set number of doses at a set price for any drug that meets a defined bar in a rare or childhood cancer, so companies know the market exists before they invest.
Modelled on Gavi's pneumococcal advance market commitment, a consortium of national payers and foundations pledges a guaranteed purchase (volume times price, for example $300 million over ten years) for the first therapy meeting a target product profile in a specified rare or paediatric indication: diffuse midline glioma, relapsed neuroblastoma, Ewing sarcoma, rare fusion-driven cancers. In exchange, the developer accepts a long-run affordable price and supply commitments. The commitment is only paid on delivery of a product that meets pre-registered efficacy criteria, so payers bear no risk of failure.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Incentives reward me-too drugs and marginal gains, Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares A non-profit pharmaceutical company for the cancers markets ignore, Incentives reward me-too drugs and marginal gains, Sarcomas (soft tissue, bone, GIST).
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Incentives reward me-too drugs and marginal gains, Neuroblastoma (paediatric).
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Sarcomas (soft tissue, bone, GIST).